Y-mAbs Therapeutics’ (YMAB) “Hold” Rating Reaffirmed at Zacks Investment Research

Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “hold” rating restated by Zacks Investment Research in a research note issued to investors on Saturday, Zacks.com reports.

According to Zacks, “Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company’s product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. “

Separately, HC Wainwright reiterated a “buy” rating and issued a $40.00 price target (up previously from $36.00) on shares of Y-mAbs Therapeutics in a report on Monday, June 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $30.80.

YMAB opened at $22.31 on Friday. The company has a current ratio of 13.30, a quick ratio of 13.30 and a debt-to-equity ratio of 0.02. The company has a market cap of $762.87 million and a PE ratio of -14.87. Y-mAbs Therapeutics has a one year low of $15.17 and a one year high of $31.00.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Friday, March 22nd. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.11). As a group, equities research analysts predict that Y-mAbs Therapeutics will post -1.95 earnings per share for the current year.

In related news, insider Thomas Gad sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $20.61, for a total value of $123,660.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 270,000 shares of company stock valued at $6,888,700 in the last quarter.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC lifted its holdings in Y-mAbs Therapeutics by 32.2% during the fourth quarter. FMR LLC now owns 1,626,642 shares of the company’s stock worth $33,086,000 after buying an additional 396,000 shares during the period. Millennium Management LLC lifted its holdings in Y-mAbs Therapeutics by 20.9% during the fourth quarter. Millennium Management LLC now owns 386,919 shares of the company’s stock worth $7,870,000 after buying an additional 67,013 shares during the period. BlackRock Inc. lifted its holdings in Y-mAbs Therapeutics by 2,178.9% during the fourth quarter. BlackRock Inc. now owns 341,831 shares of the company’s stock worth $6,952,000 after buying an additional 326,831 shares during the period. Vanguard Group Inc purchased a new stake in Y-mAbs Therapeutics during the third quarter worth $2,260,000. Finally, Vanguard Group Inc. purchased a new stake in Y-mAbs Therapeutics during the third quarter worth $2,260,000. Hedge funds and other institutional investors own 24.80% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Recommended Story: Bear Market

Get a free copy of the Zacks research report on Y-mAbs Therapeutics (YMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.